NASDAQ Biotechnology Index


Also found in: Wikipedia.

NASDAQ Biotechnology Index

An index tracking pharmaceutical, biological research and similar companies whose shares trade on NASDAQ. It is weighted under a modified market capitalization scheme; the securities that compose it are updated semi-annually.
References in periodicals archive ?
M2 PHARMA-December 19, 2017-GlycoMimetics to Join NASDAQ Biotechnology Index
declared that it has been chosen or inclusion to the NASDAQ Biotechnology Index.
The Nasdaq Biotechnology Index is a modified capitalization-weighted index that includes Nasdaq-listed companies classified as either biotechnology or pharmaceutical.
After a year of remarkable gains--accentuated by a near-record number of initial public offerings (IPOs) and 61 percent rise in the NASDAQ Biotechnology Index (the gain is more than double the S&P 500's 26 percent growth in 2013)--biotech stocks have significantly lost their luster.
The Nasdaq biotechnology index fell seven per cent for the week.
Biotechnology companies in particular had a standout 2013, with the Nasdaq Biotechnology Index gaining 66 per cent, topping a 30 per cent increase for the Standard & Poor's 500, and closing on Thursday at a record high of 2,449.
M2 EQUITYBITES-December 24, 2013-Agios Pharmaceuticals announces addition to Nasdaq Biotechnology Index
The firm cites the iShares NASDAQ biotechnology Index, the SPDR S&P Biotech ETF and the First Trust AMEX biotechnology Index ETF, which have all gained over 20% in the past year and outperformed the broader markets by a good margin.
The ETFs seek to provide 200 per cent or -200 per cent of the return of the NASDAQ Biotechnology Index for a single day.
AVANIR Pharmaceuticals has been selected for addition to the NASDAQ Biotechnology Index effective Monday, November 20.
has been selected for inclusion in the Nasdaq Biotechnology Index, which tracks the performance of the pharmaceutical and biotechnology market sectors.